Henry Schein Reports Record Fourth Quarter Results

EPS up 9.6% to $1.26

Feb 13, 2013, 07:00 ET from Henry Schein, Inc.

MELVILLE, N.Y., Feb. 13, 2013 /PRNewswire/ -- Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, medical and animal health practitioners, today reported record financial results for the quarter ended December 29, 2012.

The Company is on a 52/53 week fiscal year ending on the last Saturday in December, and 2011 had an extra selling week compared with 2012.  That extra selling week occurred in the fourth quarter of 2011.  In order to facilitate a more meaningful analysis, the Company has estimated the impact of the extra week on sales growth and is providing internal sales growth in local currencies excluding that extra week.

Net sales for the fourth quarter of 2012 were $2.4 billion, an increase of 2.9% compared with the fourth quarter of 2011.  This consisted of internal growth in local currencies of 6.0%, acquisition growth of 5.0% and decreases related to foreign currency exchange and the extra week of 0.6% and 7.5% respectively. 

Net income attributable to Henry Schein, Inc. for the fourth quarter of 2012 was $112.5 million or $1.26 per diluted share, an increase of 7.4% and 9.6%, respectively, compared with the fourth quarter of 2011.

"Once again we believe we gained market share during the quarter in each of our business groups, driven by strong domestic results across the board and despite some challenges in certain overseas markets.  Profitability also was strong with growth in diluted EPS of approximately 10%, and we are pleased to be affirming EPS guidance for 2013," commented Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein.

Global Dental sales of $1.3 billion declined 2.4%, and included internal growth in local currencies of 3.6%, acquisition growth of 2.6% and decreases related to foreign currency exchange and the extra week of 0.9% and 7.7% respectively.  Internal growth in local currencies of 3.6% included 7.0% growth in North America and a decline in International growth of 1.5%.

"We are delighted to report continued strength in North America Dental equipment with growth of 21.9% and overall growth in North America Dental of 7.0%.  While International Dental merchandise internal growth in local currencies was a healthy 2.2%, a decline in equipment sales of 9.2% reflects a cautious spending environment in much of Europe, particularly in Germany and the Netherlands, as well as in Australia," commented Mr. Bergman. "In Germany, we believe that equipment sales were negatively impacted by the timing of the upcoming IDS show in Cologne."  The company noted that all quoted sales growth rates are adjusted to exclude the impact of the extra week in 2011. 

Global Animal Health sales of $611.2 million increased 16.1%, and included internal growth in local currencies of 10.6%, acquisition growth of 13.7% and decreases related to foreign currency exchange and the extra week of 0.3% and 7.9% respectively.  Internal growth in local currencies of 10.6% included 18.4% growth in North America and 3.1% International growth.

"We continued to gain market share in our Global Animal Health business during the fourth quarter with accelerated internal growth in North America, excluding the extra week, compared with the preceding quarter," commented Mr. Bergman.  "Internal growth in local currencies in our International Animal Health business remained healthy, yet slowed somewhat primarily due to macroeconomic factors."

Global Medical sales of $402.4 million increased 1.1%, and included internal growth in local currencies of 6.9%, acquisition growth of 1.4% and decreases related to foreign currency exchange and the extra week of 0.3% and 6.9% respectively.  Internal growth in local currencies of 6.9% included 7.2% growth in North America and 2.9% International growth.

"We are very pleased with the results from our Global Medical business, with growth in North America significantly higher than in the third quarter and International Medical returning to positive internal growth in local currencies, both excluding the impact of the extra week.  We sold approximately 1.4 million doses of influenza vaccine during the quarter, as expected, and sold approximately 8.3 million doses for the full year," remarked Mr. Bergman.

Global Technology and Value-Added Services sales of $81.4 million increased 15.0%, and included internal growth in local currencies of 13.5%, acquisition growth of 6.5%, an increase related to foreign currency exchange of 0.2% and a decrease due to the extra week of 5.2%.  Internal growth in local currencies of 13.5% included 15.7% growth in North America and a decline in International growth of 1.0%.

"Technology and Value-Added Services sales growth accelerated during the quarter in North America, which represented nearly 90% of the group's revenues, and included particular strength in recurring revenue streams on both the technology and financial services.  Our European technology business was impacted by continued macroeconomic issues," commented Mr. Bergman.

Stock Repurchase Plan The Company announced that it repurchased approximately 1.1 million shares of its common stock during the fourth quarter at an average price of $79.50 per share, or approximately $84.2 million.  The impact of the repurchase of shares on fourth quarter diluted EPS was immaterial.  At the close of the fourth quarter, Henry Schein had $300 million authorized for future repurchases of its common stock.

2012 Annual Results For 2012 net sales of $8.9 billion increased 4.8% compared with 2011.  This consisted of internal growth in local currencies of 5.1%, acquisition growth of 3.1% and decreases related to foreign currency exchange and the extra week of 1.9% and 1.5% respectively.  

Net income attributable to Henry Schein, Inc. for 2012 was $388.1 million or $4.32 per diluted share.  Excluding restructuring costs of $15.2 million pre-tax or $0.12 per diluted share, net income attributable to Henry Schein, Inc. for 2012 was $398.6 million or $4.44 per diluted share, an increase of 8.4% and 11.8%, respectively, compared with 2011 (see Exhibit B for reconciliation of GAAP net income and EPS to non-GAAP adjusted net income and EPS).

Debt Refinancing  During 2013 the Company intends to refinance the debt of approximately $220 million related to the Butler Schein Animal Health transaction.  The refinancing is expected to reduce interest expense and to be accretive to EPS by $0.02 to $0.03 on an annualized basis.  The Company expects the refinancing to occur at the end of the first quarter of 2013.  As part of that refinancing, the Company expects to incur a one-time, non-cash charge of approximately $0.04 to $0.05 per diluted share.

2013 EPS Guidance Henry Schein today affirmed 2013 financial guidance, as follows:

  • For 2013 the Company expects diluted EPS attributable to Henry Schein, Inc. to be $4.81 to $4.91, which represents growth of 8% to 11% compared with 2012 results excluding restructuring costs.
  • Guidance for 2013 diluted EPS attributable to Henry Schein, Inc. excludes the one-time, non-cash charge of approximately $0.04 to $0.05 per diluted share related to the refinancing of Butler Schein Animal Health debt, as discussed above.
  • Guidance for 2013 diluted EPS attributable to Henry Schein, Inc. is for current continuing operations as well as completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any.

Fourth Quarter Conference Call Webcast The Company will hold a conference call to discuss fourth quarter financial results today, beginning at 10:00 a.m. Eastern time.  Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at www.henryschein.com.  In addition, a replay will be available beginning shortly after the call has ended.

About Henry Schein, Inc. Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental, medical and animal health practitioners.  The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites.  A Fortune 500® Company and a member of the NASDAQ 100® Index, Henry Schein employs more than 15,000 Team Schein Members and serves more than 775,000 customers.

The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care.  Henry Schein operates through a centralized and automated distribution network, with a selection of more than 96,000 branded products and Henry Schein private-brand products in stock, as well as more than 110,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.

Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 25 countries.  The Company's sales reached a record $8.9 billion in 2012, and have grown at a compound annual rate of 17 percent since Henry Schein became a public company in 1995.  For more information, visit the Henry Schein Web site at www.henryschein.com.

Cautionary Note Regarding Forward-Looking Statements

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein.  All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance.  These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms.  A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: effects of a highly competitive market; our dependence on third parties for the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion of customer purchasing power and multi-tiered costing structures; possible increases in the cost of shipping our products or other service issues with our third-party shippers; general global macro-economic conditions; disruptions in financial markets; possible volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy laws; risks associated with our global operations; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies; financial risks associated with acquisitions and joint ventures; litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; risks from rapid technological change; risks from disruption to our information systems; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority. 

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict.  Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results.  We undertake no duty and have no obligation to update forward-looking statements.

(TABLES TO FOLLOW)

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

Three Months Ended

Years Ended

December 29,

December 31,

December 29,

December 31,

2012

2011

2012

2011

(unaudited)

(unaudited)

Net sales

$

2,408,438

$

2,340,148

$

8,939,967

$

8,530,242

Cost of sales

1,744,943

1,687,559

6,432,454

6,112,187

Gross profit

663,495

652,589

2,507,513

2,418,055

Operating expenses:

Selling, general and administrative

482,153

489,216

1,873,360

1,835,906

Restructuring costs

-

-

15,192

-

Operating income

181,342

163,373

618,961

582,149

Other income (expense):

Interest income

3,172

3,638

13,394

15,593

Interest expense

(8,243)

(7,577)

(30,902)

(30,377)

Other, net

392

629

2,735

1,942

Income before taxes and equity in earnings (losses)

    of affiliates

176,663

160,063

604,188

569,307

Income taxes

(54,108)

(49,458)

(187,858)

(180,212)

Equity in earnings (losses) of affiliates

(840)

5,216

7,058

15,561

Net income

121,715

115,821

423,388

404,656

Less: Net income attributable to noncontrolling interests

(9,248)

(11,091)

(35,312)

(36,995)

Net income attributable to Henry Schein, Inc.

$

112,467

$

104,730

$

388,076

$

367,661

Earnings per share attributable to Henry Schein, Inc.:

Basic

$

1.29

$

1.18

$

4.44

$

4.08

Diluted

$

1.26

$

1.15

$

4.32

$

3.97

Weighted-average common shares outstanding:

Basic

87,002

88,758

87,499

90,120

Diluted

89,284

91,242

89,823

92,620

 

 

HENRY SCHEIN, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

December 29,

December 31,

2012

2011

ASSETS

Current assets:

Cash and cash equivalents

$

122,080

$

147,284

Accounts receivable, net of reserves of $75,240 and $65,853

1,015,194

888,248

Inventories, net

1,203,507

947,849

Deferred income taxes

64,049

54,970

Prepaid expenses and other

299,547

234,157

Total current assets

2,704,377

2,272,508

Property and equipment, net

273,458

262,088

Goodwill

1,601,046

1,497,108

Other intangibles, net

462,182

409,612

Investments and other

292,934

298,828

Total assets

$

5,333,997

$

4,740,144

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

$

787,658

$

621,468

Bank credit lines

27,166

55,014

Current maturities of long-term debt

17,992

22,819

Accrued expenses:

Payroll and related

207,381

191,173

Taxes

132,774

121,234

Other

299,738

259,932

Total current liabilities

1,472,709

1,271,640

Long-term debt

488,121

363,524

Deferred income taxes

196,814

188,739

Other liabilities

125,314

80,568

Total liabilities

2,282,958

1,904,471

Redeemable noncontrolling interests

435,175

402,050

Commitments and contingencies

Stockholders' equity:

   Preferred stock, $.01 par value, 1,000,000 shares authorized,

none outstanding

-

-

Common stock, $.01 par value, 240,000,000 shares authorized,

87,850,671 outstanding on December 29, 2012 and

89,928,082 outstanding on December 31, 2011

879

899

Additional paid-in capital

375,946

401,262

Retained earnings

2,183,905

2,007,477

Accumulated other comprehensive income

52,855

22,584

Total Henry Schein, Inc. stockholders' equity

2,613,585

2,432,222

Noncontrolling interests

2,279

1,401

Total stockholders' equity

2,615,864

2,433,623

Total liabilities, redeemable noncontrolling interests and stockholders' equity

$

5,333,997

$

4,740,144

 

 

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Three Months Ended

Years Ended

December 29,

December 31,

December 29,

December 31,

2012

2011

2012

2011

(unaudited)

(unaudited)

Cash flows from operating activities:

Net income

$

121,715

$

115,821

$

423,388

$

404,656

Adjustments to reconcile net income to net cash

provided by operating activities:

Depreciation and amortization

33,333

29,856

125,322

115,896

Stock-based compensation expense

5,446

10,887

37,313

36,932

Provision for losses on trade and other

accounts receivable

1,069

2,520

4,407

6,156

Provision for (benefit from) deferred income taxes

18,550

(6,491)

10,072

(19,319)

Stock issued to 401(k) plan

-

-

-

5,798

Equity in (earnings) losses of affiliates

840

(5,216)

(7,058)

(15,561)

Distributions from equity affiliates

5,202

4,725

14,499

14,883

Other

3,705

3,324

14,193

6,352

Changes in operating assets and liabilities,

  net of acquisitions:

Accounts receivable

32,036

86,989

(73,925)

36,204

Inventories

(108,558)

(29,498)

(193,585)

(44,155)

Other current assets

(35,602)

8,044

(62,390)

(10,493)

Accounts payable and accrued expenses

121,925

56,865

115,863

17,276

Net cash provided by operating activities

199,661

277,826

408,099

554,625

Cash flows from investing activities:

Purchases of fixed assets

(18,303)

(12,629)

(51,237)

(45,176)

Payments for equity investments and business

acquisitions, net of cash acquired

(13,977)

(5,767)

(220,238)

(149,403)

Proceeds from sales of available-for-sale securities

3,200

150

9,225

2,600

Other

(3,224)

(2,263)

(7,354)

(1,243)

Net cash used in investing activities

(32,304)

(20,509)

(269,604)

(193,222)

Cash flows from financing activities:

Proceeds from (repayments of) bank borrowings

(130,246)

14,917

(32,185)

13,316

Proceeds from issuance of long-term debt

50,000

-

155,132

3,101

Debt issuance costs

(78)

-

(1,482)

(2,847)

Principal payments for long-term debt

(2,505)

(9,066)

(40,722)

(33,722)

Proceeds from issuance of stock upon exercise

of stock options

28,712

4,269

72,485

34,519

Payments for repurchases of common stock

(84,194)

(67,527)

(299,883)

(200,002)

Excess tax benefits related to stock-based

compensation

7,176

1,340

17,819

8,765

Distributions to noncontrolling shareholders

(9,703)

(2,177)

(21,284)

(10,055)

Acquisitions of noncontrolling interests in

subsidiaries

(468)

(155,000)

(20,481)

(170,199)

Other

-

-

-

(90)

Net cash used in financing activities

(141,306)

(213,244)

(170,601)

(357,214)

Net change in cash and cash equivalents

26,051

44,073

(32,106)

4,189

Effect of exchange rate changes on cash and

cash equivalents

6,693

(3,661)

6,902

(7,253)

Cash and cash equivalents, beginning of period

89,336

106,872

147,284

150,348

Cash and cash equivalents, end of period

$

122,080

$

147,284

$

122,080

$

147,284

Note: Certain prior period amounts have been reclassified to conform to the current period presentation.

 

 

Exhibit A1 - QTD Sales

Henry Schein, Inc.

2012 Fourth Quarter

Sales Summary

(in thousands)

(unaudited)

Q4 2012 over Q4 2011

Global

Q4 2012

Q4 2011

Total Sales Growth

   Dental

$

1,313,467

$

1,345,289

-2.4%

   Animal Health

611,179

526,217

16.1%

   Medical

402,435

397,917

1.1%

Total Health Care Distribution

2,327,081

2,269,423

2.5%

Technology and value-added services

81,357

70,725

15.0%

Total Global

$

2,408,438

$

2,340,148

2.9%

North America

Q4 2012

Q4 2011

Total Sales Growth

   Dental

$

807,597

$

813,378

-0.7%

   Animal Health

281,592

255,858

10.1%

   Medical

380,850

374,665

1.7%

Total Health Care Distribution

1,470,039

1,443,901

1.8%

Technology and value-added services

71,323

61,619

15.7%

Total North America

$

1,541,362

$

1,505,520

2.4%

International

Q4 2012

Q4 2011

Total Sales Growth

   Dental

$

505,870

$

531,911

-4.9%

   Animal Health

329,587

270,359

21.9%

   Medical

21,585

23,252

-7.2%

Total Health Care Distribution

857,042

825,522

3.8%

Technology and value-added services

10,034

9,106

10.2%

Total International

$

867,076

$

834,628

3.9%

 

 

Exhibit A1 - YTD Sales

Henry Schein, Inc.

2012 Fourth Quarter Year to Date

Sales Summary

(in thousands)

(unaudited)

Q4 2012 YTD over Q4 2011 YTD

Global

Q4 2012 YTD

Q4 2011 YTD

Total Sales Growth

   Dental

$

4,774,482

$

4,764,898

0.2%

   Animal Health

2,321,151

2,010,270

15.5%

   Medical

1,560,921

1,504,454

3.8%

Total Health Care Distribution

8,656,554

8,279,622

4.6%

Technology and value-added services

283,413

250,620

13.1%

Total Global

$

8,939,967

$

8,530,242

4.8%

North America

Q4 2012 YTD

Q4 2011 YTD

Total Sales Growth

   Dental

$

2,960,129

$

2,884,257

2.6%

   Animal Health

1,122,273

993,182

13.0%

   Medical

1,479,775

1,417,071

4.4%

Total Health Care Distribution

5,562,177

5,294,510

5.1%

Technology and value-added services

245,385

216,279

13.5%

Total North America

$

5,807,562

$

5,510,789

5.4%

International

Q4 2012 YTD

Q4 2011 YTD

Total Sales Growth

   Dental

$

1,814,353

$

1,880,641

-3.5%

   Animal Health

1,198,878

1,017,088

17.9%

   Medical

81,146

87,383

-7.1%

Total Health Care Distribution

3,094,377

2,985,112

3.7%

Technology and value-added services

38,028

34,341

10.7%

Total International

$

3,132,405

$

3,019,453

3.7%

 

 

Exhibit A2 - QTD Sales Growth

Henry Schein, Inc.

2012 Fourth Quarter

Sales Growth Rate Summary

(unaudited)

Q4 2012 over Q4 2011

Global

Consolidated

Dental

Animal Health

Medical

Technology/VAS

Local Internal Sales Growth

6.0%

3.6%

10.6%

6.9%

13.5%

Prior Year Extra Week Impact

-7.5%

-7.7%

-7.9%

-6.9%

-5.2%

Acquisitions

5.0%

2.6%

13.7%

1.4%

6.5%

Local Currency Sales Growth

3.5%

-1.5%

16.4%

1.4%

14.8%

Foreign Currency Exchange

-0.6%

-0.9%

-0.3%

-0.3%

0.2%

     Total Sales Growth

2.9%

-2.4%

16.1%

1.1%

15.0%

Total sales growth excluding

influenza vaccine sales

2.9%

1.3%

Local currency internal sales growth

excluding influenza vaccine sales

6.1%

7.3%

North America

Consolidated

Dental

Animal Health

Medical

Technology/VAS

Local Internal Sales Growth

9.4%

7.0%

18.4%

7.2%

15.7%

Prior Year Extra Week Impact

-8.3%

-9.1%

-8.3%

-7.0%

-5.6%

Acquisitions

1.1%

1.1%

0.0%

1.5%

5.5%

Local Currency Sales Growth

2.2%

-1.0%

10.1%

1.7%

15.6%

Foreign Currency Exchange

0.2%

0.3%

0.0%

0.0%

0.1%

     Total Sales Growth

2.4%

-0.7%

10.1%

1.7%

15.7%

Total sales growth excluding

influenza vaccine sales

2.4%

1.8%

Local currency internal sales growth

excluding influenza vaccine sales

9.5%

7.6%

International

Consolidated

Dental

 Animal Health

Medical

Technology/VAS

Local Internal Sales Growth

0.1%

-1.5%

3.1%

2.9%

-1.0%

Prior Year Extra Week Impact

-6.2%

-5.7%

-7.3%

-6.2%

-3.1%

Acquisitions

12.0%

5.0%

26.7%

0.0%

12.9%

Local Currency Sales Growth

5.9%

-2.2%

22.5%

-3.3%

8.8%

Foreign Currency Exchange

-2.0%

-2.7%

-0.6%

-3.9%

1.4%

     Total Sales Growth

3.9%

-4.9%

21.9%

-7.2%

10.2%

 

 

Exhibit A2 - YTD Sales Growth

Henry Schein, Inc.

2012 Fourth Quarter Year to Date

Sales Growth Rate Summary

(unaudited)

Q4 2012 YTD over Q4 2011 YTD

Global

Consolidated

Dental

Animal Health

Medical

Technology/VAS

Local Internal Sales Growth

5.1%

2.8%

10.2%

4.8%

10.8%

Prior Year Extra Week Impact

-1.5%

-1.5%

-1.6%

-1.5%

-1.5%

Acquisitions

3.1%

1.2%

9.1%

0.9%

4.1%

Local Currency Sales Growth

6.7%

2.5%

17.7%

4.2%

13.4%

Foreign Currency Exchange

-1.9%

-2.3%

-2.2%

-0.4%

-0.3%

     Total Sales Growth

4.8%

0.2%

15.5%

3.8%

13.1%

Total sales growth excluding

influenza vaccine sales

5.0%

4.8%

Local currency internal sales growth

excluding influenza vaccine sales

5.3%

5.9%

North America

Consolidated

Dental

Animal Health

Medical

Technology/VAS

Local Internal Sales Growth

6.5%

4.0%

15.0%

5.0%

12.0%

Prior Year Extra Week Impact

-1.8%

-2.0%

-2.0%

-1.5%

-1.7%

Acquisitions

0.8%

0.8%

0.0%

0.9%

3.2%

Local Currency Sales Growth

5.5%

2.8%

13.0%

4.4%

13.5%

Foreign Currency Exchange

-0.1%

-0.2%

0.0%

0.0%

0.0%

     Total Sales Growth

5.4%

2.6%

13.0%

4.4%

13.5%

Total sales growth excluding

influenza vaccine sales

5.7%

5.6%

Local currency internal sales growth

excluding influenza vaccine sales

6.9%

6.2%